Arcus Biosciences, Inc. Cash and Cash Equivalents, Fair Value Disclosure
Arcus Biosciences, Inc. (RCUS) had Cash and Cash Equivalents, Fair Value Disclosure of $150.00 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Fair Value Disclosures
us-gaap:CashAndCashEquivalentsFairValueDisclosure · last filed 2026-08-05
- 2026-06-30: Cash and Cash Equivalents, Fair Value Disclosure $150.00M.
- 2026-03-31: Cash and Cash Equivalents, Fair Value Disclosure $201.00M.
- 2025-12-31: Cash and Cash Equivalents, Fair Value Disclosure $222.00M.
- 2025-09-30: Cash and Cash Equivalents, Fair Value Disclosure $238.00M.
| Period end | Cash and Cash Equivalents, Fair Value Disclosure | Cash and Cash Equivalents, Fair Value Disclosure as first filed |
|---|---|---|
| 2026-06-30 | $150.00M 10-Q · filed 2026-08-05 | |
| 2026-03-31 | $201.00M 10-Q · filed 2026-05-05 | |
| 2025-12-31 | $222.00M 10-Q · filed 2026-08-05 | |
| 2025-09-30 | $238.00M 10-Q · filed 2025-10-28 | |
| 2025-06-30 | $248.00M 10-Q · filed 2025-08-06 | |
| 2025-03-31 | $192.00M 10-Q · filed 2025-05-06 | |
| 2024-12-31 | $150.00M 10-K · filed 2026-02-25 | |
| 2024-09-30 | $201.00M 10-Q · filed 2024-11-06 | |
| 2024-06-30 | $156.00M 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $185.00M 10-Q · filed 2024-05-08 | |
| 2023-12-31 | $127.00M 10-K · filed 2025-02-25 | |
| 2023-09-30 | $184.00M 10-Q · filed 2023-11-07 | |
| 2023-06-30 | $230.00M 10-Q · filed 2023-08-07 | |
| 2023-03-31 | $238.00M 10-Q · filed 2023-05-09 | |
| 2022-12-31 | $206.00M 10-K · filed 2024-02-21 | |
| 2022-09-30 | $217.65M 10-Q · filed 2022-11-02 | |
| 2022-06-30 | $272.63M 10-Q · filed 2022-08-03 | |
| 2022-03-31 | $548.78M 10-Q · filed 2022-05-09 | |
| 2021-12-31 | $148.00M 10-K · filed 2023-02-28 | $147.91M 10-K · filed 2022-02-23 |
| 2021-09-30 | $179.43M 10-Q · filed 2021-11-08 | |
| 2021-06-30 | $320.48M 10-Q · filed 2021-08-05 | |
| 2021-03-31 | $390.26M 10-Q · filed 2021-05-05 | |
| 2020-12-31 | $173.41M 10-K · filed 2022-02-23 | |
| 2020-09-30 | $221.85M 10-Q · filed 2020-11-05 | |
| 2020-06-30 | $285.19M 10-Q · filed 2020-08-06 | |
| 2020-03-31 | $67.33M 10-Q · filed 2020-05-05 | |
| 2019-12-31 | $57.94M 10-K · filed 2021-02-25 | |
| 2019-09-30 | $78.99M 10-Q · filed 2019-11-05 | |
| 2019-06-30 | $76.07M 10-Q · filed 2019-08-06 | |
| 2019-03-31 | $68.50M 10-Q · filed 2019-05-02 | |
| 2018-12-31 | $71.06M 10-K · filed 2020-03-05 | |
| 2018-09-30 | $74.89M 10-Q · filed 2018-11-08 | |
| 2018-06-30 | $170.00M 10-Q · filed 2018-08-06 | |
| 2018-03-31 | $198.12M 10-Q · filed 2018-05-09 | |
| 2017-12-31 | $98.43M 10-K · filed 2019-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |